These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

415 related items for PubMed ID: 34878300

  • 1. Minimum Inhibitory Concentrations before and after Antibacterial Treatment in Patients with Mycobacterium abscessus Pulmonary Disease.
    Fujiwara K, Uesugi F, Furuuchi K, Tanaka Y, Yoshiyama T, Saotome M, Ohta K, Mitarai S, Morimoto K.
    Microbiol Spectr; 2021 Dec 22; 9(3):e0192821. PubMed ID: 34878300
    [Abstract] [Full Text] [Related]

  • 2. Subspecies Distribution and Antimicrobial Susceptibility Testing of Mycobacterium abscessus Clinical Isolates in Madrid, Spain: a Retrospective Multicenter Study.
    Ruedas-López A, Tato M, Broncano-Lavado A, Esteban J, Ruiz-Serrano MJ, Sánchez-Cueto M, Toro C, Domingo D, Cacho J, Barrado L, López-Roa P.
    Microbiol Spectr; 2023 Jun 15; 11(3):e0504122. PubMed ID: 37212700
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. M ycobacterium abscessus pulmonary disease: individual patient data meta-analysis.
    Kwak N, Dalcolmo MP, Daley CL, Eather G, Gayoso R, Hasegawa N, Jhun BW, Koh WJ, Namkoong H, Park J, Thomson R, van Ingen J, Zweijpfenning SMH, Yim JJ.
    Eur Respir J; 2019 Jul 15; 54(1):. PubMed ID: 30880280
    [Abstract] [Full Text] [Related]

  • 7. Outcomes of Inhaled Amikacin-Containing Multidrug Regimens for Mycobacterium abscessus Pulmonary Disease.
    Kang N, Jeon K, Kim H, Kwon OJ, Huh HJ, Lee NY, Daley CL, Koh WJ, Jhun BW.
    Chest; 2021 Aug 15; 160(2):436-445. PubMed ID: 33621600
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Clinical characteristics and antimicrobial susceptibility profiles of Mycobacterium abscessus and Mycobacterium massiliense pulmonary infection.
    Guo W, Shangguan Y, Ji Z, Hu M, Li X, Hu W, Zheng L, Huang S, Wang Y, Xia J, Jiang L, Xu K.
    J Glob Antimicrob Resist; 2024 Sep 15; 38():83-89. PubMed ID: 38719186
    [Abstract] [Full Text] [Related]

  • 10. In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium abscessus Complex.
    Brown-Elliott BA, Wallace RJ.
    Antimicrob Agents Chemother; 2019 Feb 15; 63(2):. PubMed ID: 30509936
    [Abstract] [Full Text] [Related]

  • 11. The synergetic effect of Imipenem-clarithromycin combination in the Mycobacteroides abscessus complex.
    Takei S, Ihara H, Togo S, Nakamura A, Fujimoto Y, Watanabe J, Kurokawa K, Shibayama K, Sumiyoshi I, Ochi Y, Iwai M, Okabe T, Chonan M, Misawa S, Ohsaka A, Takahashi K.
    BMC Microbiol; 2020 Oct 19; 20(1):316. PubMed ID: 33076820
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Mycobacteriological characteristics and treatment outcomes in extrapulmonary Mycobacterium abscessus complex infections.
    Jeong SH, Kim SY, Huh HJ, Ki CS, Lee NY, Kang CI, Chung DR, Peck KR, Shin SJ, Koh WJ.
    Int J Infect Dis; 2017 Jul 19; 60():49-56. PubMed ID: 28522316
    [Abstract] [Full Text] [Related]

  • 14. Comparison of drug-susceptibility patterns and gene sequences associated with clarithromycin and azithromycin resistance in Mycobacterium abscessus complex isolates and evaluation of the accumulation of intrinsic macrolide resistance.
    Yoshida S, Tsuyuguchi K, Kobayashi T, Inoue Y, Suzuki K.
    J Med Microbiol; 2021 Mar 19; 70(3):. PubMed ID: 33570485
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense.
    Park J, Cho J, Lee CH, Han SK, Yim JJ.
    Clin Infect Dis; 2017 Feb 01; 64(3):301-308. PubMed ID: 28011609
    [Abstract] [Full Text] [Related]

  • 17. Nationwide surveillance of antimicrobial susceptibility of 509 rapidly growing mycobacteria strains isolated from clinical specimens in Japan.
    Kamada K, Yoshida A, Iguchi S, Arai Y, Uzawa Y, Konno S, Shimojima M, Kikuchi K.
    Sci Rep; 2021 Jun 09; 11(1):12208. PubMed ID: 34108590
    [Abstract] [Full Text] [Related]

  • 18. Aortic endograft infection by Mycobacterium abscessus subsp. massiliense with acquired clarithromycin resistance: a case report.
    Akiyama Y, Iwamoto N, Kamada K, Yoshida A, Osugi A, Mitarai S, Suzuki T, Yamamoto K, Nagashima M, Horai T, Ohmagari N.
    BMC Infect Dis; 2023 Oct 17; 23(1):694. PubMed ID: 37848843
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. In Vitro Synergism of Rifabutin with Clarithromycin, Imipenem, and Tigecycline against the Mycobacterium abscessus Complex.
    Cheng A, Tsai YT, Chang SY, Sun HY, Wu UI, Sheng WH, Chen YC, Chang SC.
    Antimicrob Agents Chemother; 2019 Apr 17; 63(4):. PubMed ID: 30670428
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.